Trebananib was associated with more adverse event-related treatment discontinuations than was placebo ( 77 [ 17 % ] patients vs 27 [ 6 % ] , respectively ) and higher incidences of oedema ( 294 [ 64 % ] patients had any-grade oedema in the trebananib group vs 127 [ 28 % ] patients in the placebo group ) .